Pelthos Therapeutics reports strong third-quarter results, highlighted by the successful launch of ZELSUVMI and significant investor backing, positioning the company for future growth in the pediatric topical treatment market.
- Generated $7.1 million in net product revenue primarily from strong demand for ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum.
- Completed a $50 million PIPE financing to support ZELSUVMI's launch and a subsequent $18 million convertible notes financing for the acquisition of Xepi.
- Expect cash flow breakeven from operations before the end of 2026, driven by ZELSUVMI's growth.
- Sales force expansion planned with the addition of 14 representatives to enhance market coverage and accelerate sales growth.
- The market for molluscum contagiosum presents substantial opportunity with an estimated 6 million new cases annually in the U.S.
Community Discussion